soul trial oral semaglutide cardiovascular outcomes results 2025 nejm In the OASIS 4 phase 3 trial, once-daily at a dose of 25 mg resulted in a greater mean reduction in body weight than placebo in participants with overweight or soul trial oral semaglutide cardiovascular
Pay in 4 interest-free payments of $6.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31



























